Építés alatt – nem éles oldal
Belépés
Résztvevőt keres1. fázis

Safety and Efficacy of CD19 Chimeric Antigen Receptor T-Cell (CAR-T) in the Treatment of Refractory Membranous Nephropathy

A legfontosabb adatok

Ki végzi
The First Affiliated Hospital of Air Force Medical University
Hol
Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toboroz
Fázis
1. fázis
Résztvevők
5 fő, tervezett
Kezdés
2025. dec. 8.
Várható befejezés
2028. júl. 31.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • All patients will receive CD19 CAR-T cell therapy on the basis of standard symptomatic and supportive treatment.
A regiszteradat frissítve
2025. december 24.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 17 feltétel megnézéseKevesebb

Ki vehet részt

  • Confirmed as primary membranous nephropathy (PMN) by renal biopsy
  • Classified as moderate-risk or high-risk refractory membranous nephropathy (rMN)
  • Moderate-risk rMN is defined as: eGFR ≥ 90 ml/min/1.73m² AND 24-hour urinary protein > 3.5g/d, with a reduction of no more than 50% within 6 months of receiving renin-angiotensin system inhibitor (RASi) therapy
  • High-risk rMN is defined as meeting one of the following:; eGFR < 60 ml/min/1.73m² and/or persistent proteinuria > 8g/d for more than 6 months; Normal eGFR with proteinuria > 3.5g/d and ≤50% reduction after 6 months of RASi therapy, PLUS at least one of the following: Serum albumin < 25g/L; PLA2R antibody > 50 RU/mL; Urinary α1-microglobulin > 40 μg/min; Urinary IgG > 1 μg/min; Urinary β2-microglobulin > 250 mg/d; IgG/albumin clearance ratio > 0.20
  • Diagnosis of rMN requires failure of adequate first-line immunosuppressive therapy (≥6 months of steroids+cyclophosphamide, CNI, or rituximab), defined by any of the following: persistent high-titer anti-PLA2R antibody; for antibody-negative patients, persistent nephrotic syndrome (protein >3.5g/d, albumin <30g/L); <50% reduction in proteinuria
  • Age ≥ 18 years
  • Adequate organ function, defined as:; Renal: eGFR ≥ 30 ml/min/1.73m²; Hepatic: ALT and AST ≤ 2.5 x ULN; Total bilirubin ≤ 1.5 x ULN; Cardiac: LVEF ≥ 50%; NYHA Class I or II; No significant arrhythmias requiring intervention; No major cardiovascular events within the past 6 months; Respiratory: SpO2 > 92% on room air
  • Ability to understand and willingness to sign an Informed Consent Form

Ki nem vehet részt

  • Specific treatment history or plans, including:; Prior receipt of any cell therapy (e.g., MSCs, HSCT); Major surgery within 24 weeks before or planned within 24 weeks after enrollment; Planned kidney transplantation within 3 years; History of substance abuse
  • Participation in another interventional clinical trial within 3 months prior to enrollment
  • Secondary membranous nephropathy (e.g., due to SLE, malignancy, drugs, infection)
  • Active infection requiring IV antibiotics, active tuberculosis, or positive viral serology indicating active infection, including:; HBV: HBsAg (+) and/or HBcAb (+) with detectable HBV DNA; HCV: HCV Ab (+) with detectable HCV RNA; HIV Ab (+); Active EBV or CMV infection (IgM+ or DNA above normal); Positive syphilis (Treponema pallidum) antibody (requires evaluation for active infection)
  • History of malignancy within the past 5 years, except for adequately treated non-melanoma skin cancer, cervical carcinoma in situ, or thyroid cancer
  • Inability to understand the study or provide informed consent (e.g., severe dementia, mental illness)
  • Any other condition deemed by the investigator to increase risk, interfere with assessment, or affect compliance
  • Severe uncontrolled comorbidities, including:; Uncontrolled hypertension (persistent SBP > 160 mmHg or DBP > 100 mmHg); Uncontrolled diabetes (HbA1c > 8% or random glucose ≥11.1 mmol/L) or diabetic nephropathy; Symptomatic deep vein thrombosis or pulmonary embolism within the past 6 months; Active peptic ulcer or gastrointestinal bleeding within the past 6 months; Severe congenital or acquired immunodeficiency; Severe CNS diseases (e.g., catastrophic APS, uncontrolled epilepsy); End-stage organ failure not attributable to PMN
  • Pregnant or lactating women

Ez a vizsgálat jelenleg itt érhető el: Kína.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

This study is a single-center, prospective, exploratory Phase I clinical trial initiated by the team led by Associate Professor He Lijie from the Department of Nephrology, Xijing Hospital.

A teljes eredeti leírásKevesebb

Prior to receiving CAR-T cell therapy, patients will undergo lymphodepletion chemotherapy with cyclophosphamide (fludarabine will be added if necessary). After prophylactic administration of antihistamines and acetaminophen, patients will be infused with CD19 CAR-T cells at a dose of 1×10⁶ cells/kg.

In the subsequent 2 weeks, patients will be hospitalized for monitoring of vital signs and adverse reactions. The planned follow-up duration of this study is 1 years.

A vizsgálat csoportja

  • To preliminarily evaluate the safety and efficacy of CD19 CAR-T in refractory membranous nephropathyEgyéb csoport

    Kezelés: All patients will receive CD19 CAR-T cell therapy on the basis of standard symptomatic and supportive treatment.

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Safety and Efficacy of CD19 Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T) in the Treatment of Refractory Membranous Nephropathy
A regiszteradat frissítve
2025. december 24.